Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
14 Marzo 2024 - 5:12AM
UK Regulatory
Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare
ASA, has informed the Board of Directors that she will resign from
the position on 31 March 2024, as she will assume a position as
judge in the District Court of Møre and Romsdal and will therefore
not be able to continue to serve in the position as Chair of the
Board.
Grung has been a member of the Board of Directors since December
2020, and assumed the position as Chair in April 2022. The Board
would like to thank Grung for her services for Hofseth BioCare in
this period.
Appointment of a new Chair of the Board will be proposed to the
Company's annual general meeting, to be held on 10 May 2024. In the
interim period, Roger Hofseth will function as the Chair of the
Board of Directors.
For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier
and an incubator for new pharmaceutical drug leads. Research
is ongoing to identify the individual elements within its
ingredients that modulate inflammation and the immune response with
pre-clinical studies ongoing in multiple clinics and university
research labs. Lead clinical and pre-clinical candidates are
focused on developing an oral treatment for inflammatory disease
driven by eosinophils (a type of white blood cell). Clinical trial
work with the oil is ongoing to ameliorate lung inflammation in
eosinophilic asthma and COPD ("smokers lung").
Other leads are focused on using the Company's bioactive
peptides as a Medical Food for the protection of the
Gastro- Intestinal (GI) system against inflammation (including
ulcerative colitis and the orphan condition necrotizing
enterocolitis). The Company is founded on the core values of
sustainability, optimal utilization of natural
resources and full traceability. Through innovative and
patent protected hydrolysis technology, HBC can preserve the
quality of the lipids, proteins and calcium from fresh salmon
off-cuts.
HBC's headquarters are in Ålesund, Norway with offices in Oslo,
London, Zürich, New Jersey and Palo Alto, CA.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
Hofseth Biocare Asa (LSE:0Q6H)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Hofseth Biocare Asa (LSE:0Q6H)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024